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Mechanisms underlying childhood arterial ischemic stroke (AIS) are heterogeneous and poorly understood 
but critical for the development of targeted interventions. 
Current evidence suggests interplay between (mostly) rare ge-
netic risk factors and common environmental exposures. Here, 
we explore this interplay in relation to cerebral arteriopathies 
associated with childhood AIS.
Background
Most childhood AIS is associated with nonatherosclerotic ce-
rebral arteriopathy1,2—a term encompassing any pathological 
abnormality of the arterial circulation. This nonspecific ter-
minology reflects the paucity of knowledge regarding under-
lying mechanisms. In 2014, the VIPS study (Vascular Effects 
of Infection in Pediatric Stroke) defined arteriopathy as the 
imaging appearance of an in situ arterial abnormality (ste-
nosis, irregularity, occlusion, banding, pseudoaneurysm, and 
dissection flap) not attributable to an exogenous thrombus 
(eg, cardioembolism) and not considered a normal devel-
opmental variant.3 It further defined arteriopathy subtypes 
using the 2004 consensus-based definitions described by 
Sébire et al4 and the 2012 CASCADE criteria (Childhood 
AIS Standardized Classification and Diagnostic Evaluation).5 
These definitions use radiological and clinical characteristics 
to categorize patients; however, biomarkers separating dis-
tinctive arteriopathy subtypes are still lacking.
Arteries are maintained by dynamic processes responsive 
to genetic and local signals. Congenital arteriopathies could 
reflect abnormal arterial development, whereas acquired arte-
riopathy could arise from disruptions in vascular homeostasis, 
for example, endothelial injury, repair, and angiogenesis.6
Overall, arteriopathy increases AIS recurrence risk, which 
varies with subtype.7 Diagnosis can be challenging—even 
with rigorous review, arteriopathy diagnosis could not be 
adjudicated in 34 of 355 cases.3 Careful phenotyping is im-
portant; for example, a pattern initially called moyamoya had 
distinctive features in ACTA2 mutations (Figure 1).8 It is not 
meaningful to consider all arteriopathies or AIS as a single 
group because they likely have different pathogeneses, disease 
course, and treatments.
Environmental associations with childhood AIS include 
infection and trauma. Clinically trivial viral infection and 
minor trauma are ubiquitous in childhood, yet AIS is rare—so 
additional factors, such as genetic predisposition, are likely 
to be important. Inflammation is likely to play a variety of 
roles in childhood AIS subtypes. Although monogenic causes 
of childhood AIS are rare, single-gene associations with arte-
riopathy provide important mechanistic insights. Increasingly, 
it appears that, in many of these, the interaction between ge-
netic predisposition and environmental factors is necessary to 
produce the ultimate disease phenotype.
Genetic Association With Childhood Cerebral 
Arteriopathy
The Table and Table I in the online-only Data Supplement 
summarize single-gene mutations associated with pediatric 
cerebral arteriopathy and highlight concurrent phenotypic 
features.
Moyamoya
Moyamoya is a rare, severe, and often progressive cerebral 
arteriopathy, defined radiologically by occlusive disease of 
the terminal internal carotid arteries with basal collaterals.9 
Moyamoya is divided into moyamoya disease (MMD—
primary or isolated) and moyamoya syndrome (MMS; sec-
ondary to another disease, often genetic). Children with 
moyamoya are at risk of AIS, whereas adults are more prone 
to hemorrhagic stroke. Moyamoya is arguably the most malig-
nant pediatric cerebral arteriopathy phenotype, with the high-
est risk of AIS recurrence.7,10
The strong ethnic bias (in East Asians) and 15% familial 
cases strongly implicate a genetic basis. Linkage studies 
have identified several HLA alleles associated with MMD 
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in East Asians: HLA-B35, HLA-B51, HLADRB1*04:05, 
DQB1*05:02, and *04:01. MMS is also seen in trisomy 21, 
Turner syndrome, sickle cell disease, and neurofibromatosis 
type 1 (NF1); other associations are summarized in the Table.
The p.R4810K in RNF213 polymorphism is associated 
with MMD in Japanese and Koreans.11,12 Because Japanese 
prevalence of MMD is 6/100 000, compared with 1% carrier 
rate of p.R4810K, additional factors must be required to pro-
duce moyamoya in carriers.12,13 RNF213 p.R4810K polymor-
phisms have been reported in small numbers of East Asian 
patients with other genetic diagnoses, which predispose to 
MMS, including NF1 and trisomy 21; thus RNF213 may act 
as an additional modifier.14,15 Evidence from RNF213 knock-
outs suggests that loss of function could result in vascular 
fragility and susceptibility to hemodynamic stress and other 
insults.16 Additional postulated mechanisms include a proin-
flammatory effect resulting in endothelial cell dysfunction and 
proliferation of smooth muscle cells with vascular stenosis.17
Neurofibromatosis Type 1
NF1—an autosomal dominant tumor-suppressor syndrome 
caused by mutations in the NF1 gene—is associated with 
MMS and other large-vessel arteriopathies (aneurysm and 
arterial stenosis).18,19 NF1 encodes for neurofibromin—a Ras 
pathway inhibitor. Children with NF1 have an increased risk 
of stroke, with odds ratios of 8.1 for hemorrhagic stroke and 
3.4 for AIS.20 Radiotherapy for optic glioma is an additional 
risk factor, but even discounting this cerebral arteriopathy has 
been reported in 2.5% to 6% of NF1 patients.21 Patients with 
asymptomatic MMS may show radiological progression and 
could benefit from antiplatelet therapy or revascularization.22
Neurofibromin is expressed in vascular endothelial cells, 
is a regulator of macrophage function, and is likely to have a 
role in pathogenesis. NF1 patients without arteriopathy have 
elevated levels of inflammatory cells and cytokines linked 
to vascular disease; thus, they may be susceptible to vas-
cular disease, but a second hit may be required to generate 
arteriopathy.23
Most cases of MMS in NF1 are reported in whites, and 
this also implicates additional genetic predisposition to MMS 
in NF1. RNF213 mutations have been reported in a small 
group of Korean patients with NF1 and MMS, and this may 
be a gene modifier.14
Mutations Causing Smooth Muscle  
Cell Dysfunction
ACTA2
α-Actin (encoded by ACTA2) forms a major part of the vas-
cular smooth muscle cell contractile apparatus. Heterozygous 
ACTA2 mutation carriers are at risk of vascular disorders, in-
cluding aortic aneurysm and dissection, with high attendant 
mortality.24 Heterozygous Arg179 ACTA2 mutations are as-
sociated with a distinctive cerebrovascular phenotype8 with 
proximal dilatation of carotid arteries and widespread distal 
occlusive arteriopathy. Unlike moyamoya, basal collaterals 
are absent and intracranial arteries are abnormally straight and 
broom like (Figure 1). Clinical features of smooth muscle dys-
function include congenital mydriasis and patent ductus arteri-
osus, pulmonary hypertension, bladder and bowel dysfunction, 
and livedo reticularis. It is notable that the vascular phenotype 
may be influenced by regional differences in arterial structure, 
namely dilatation of (proximal) elastin-containing segments of 
the internal carotid artery and stenosis in (distal) elastin-defi-
cient segments.25 We speculate this may be an example of the 
local environment interacting with genetic background.
MYH11
Disruptions in the smooth muscle MYH11 (myosin heavy 
chain 11), also part of the smooth muscle cell contractile ap-
paratus, are associated with thoracic aortic aneurysm or aortic 
dissection and patent ductus arteriosus. The MYH11 pheno-
type has been expanded to include moyamoya-like occlusive 
cerebrovascular disease.26
Both dominantly inherited disorders carry attendant ge-
netic implications for family members and aortic screening.
Mutations Affecting Vascular Basement 
Membranes: COL4A1 and COL4A2
COL4A1 and COL4A2 sit head-to-head on chromosome 
13q34, encoding the α1 and α2 chains of type IV collagen—
the main component of vascular basement membranes. 
Figure 1. Contrasting appearances of ACTA2 and moyamoya disease. 
Catheter cerebral angiograms (frontal projection) with right and left internal 
carotid artery (ICA) injections. Top row from a patient with R179H muta-
tion in ACTA2 showing the typical appearances of proximal ICA ectasia, 
distal ICA occlusive disease, and twig-like distal ICA branches. There are 
no basal moyamoya collaterals. In contrast, the bottom row shows images 
from an otherwise healthy girl with moyamoya disease. There is marked 
occlusive disease of both terminal ICAs with moyamoya collaterals.
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Table. Diagnostic Clues in Single Gene Causes of Pediatric Cerebral Arteriopathy
  
Genetic Mutation 
(Disease Name Given 
Below if Different)
History
Family history Stroke AD conditions: 
COL4A1, COL4A2, NF1, 
NOTCH3, SLC2A10, 
and JAG1
AR conditions: 
HBB
Cardiac disease/TAAD AD conditions: 
ACTA2 and MYH11
Neurocutaneous AD conditions: 
NF1
Consanguinity (or negative 
family history)
AR conditions: 
GUCY1A3, CECR1, 
HTRA1, SAMHD1, 
PCNT, ABCC6, and HBB
Sickle cell trait HBB
Maternal inheritance XLR conditions: 
CBS, GLA, ATP7A, and 
BRCC3/MTCP1
Neurological 
symptoms
Migraine COL4A1, COL4A2, and 
NOTCH3
Congenital hemiplegia COL4A1 and COL4A2
Developmental delay BRCC3/MTCP1, ELN, 
JAG1, SAMHD1, PCNT 
(motor), ATP7A, CBL, 
and HBB
Neuropathies CECR1 and HBB
Seizures NF1, ATP7A, SAMHD1, 
and HBB
Neurofibromata NF1
Behavioral/psychiatric NOTCH3 and HTRA1
Encephalopathy and 
regression
SAMHD1 and ATP7A
Acroparesthesia GLA
Other Intermittent fever CECR1
Achalasia GUCY1A3
Vaso-occlusive crises, 
anemia, and acute chest 
syndrome
HBB
Examination
Musculoskeletal Tall stature CBS
Short stature BRCC3/MTCP1, PCNT, 
and HBB
Scoliosis NF1
Contractures and arthropathy SAMHD1 and HBB
Joint laxity ATP7A and SLC2A10
Arachnodactyly SLC2A10
Cramps COL4A1 and COL4A2
(Continued )
Skin Livedo reticularis ACTA2, GUCY1A3, and 
CECR1,
Raynaud syndrome GUCY1A3 and SAMHD1
Chilblains SAMHD1
Axillary and inguinal  
freckling
NF1
Café-au-lait spots NF1 and PCNT
Increased laxity ABCC6
Angiokeratoderma GLA
Pallor and jaundice HBB
Hair Alopecia HTRA1
Sparse and friable ATP7A
Premature hair graying BRCC3/MTCP1
Eyes Cataracts COL4A1, COL4A2, 
BRCC3/MTCP1, and 
GLA
Retinal tortuosity COL4A1 and COL4A2
Congenital mydriasis (pupils 
fixed and dilated)
ACTA2
Optic glioma and lisch 
nodules
NF1
Peau d’orange angioid 
streaks
ABCC6
Neovascularisation and 
hemorrhage
ABCC6 and HBB
Posterior embryotoxon JAG1
Dislocated lens CBS
Facial 
dysmorphism
Hypertelorism, long philtrum, 
and mild ptosis
BRCC3/MTCP1 and 
CBL
Small upturned nose, long 
philtrum, wide mouth, full 
lips, and small chin
ELN
Microcephaly and abnormal 
teeth
PCNT
Abdomen Splenomegaly HBB
Systemic investigation findings
Cardiovascular Arrhythmia COL4A1, COL4A2, and 
GLA
Supravalvular aortic  
stenosis
ELN
PDA ACTA2, MYH11, and 
JAG1
TAAD ACTA2, MYH11, and 
CBS
Coronary artery disease ACTA2, BRCC3, and 
GLA
Pulmonary hypertension ACTA2
Table. Continued
  
Genetic Mutation 
(Disease Name Given 
Below if Different)
(Continued )
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Autosomal dominant mutations in COL4A1 result in variable 
clinical manifestations, including pediatric cerebral small 
vessel disease. COL4A2 mutations produce the same phe-
notype that includes both ischemic and hemorrhagic stroke. 
Presentation may be with early-onset hemiparesis, porenceph-
aly, and seizures or with stroke later in childhood or adult-
hood. Familial heterogeneity is common.27
Hemorrhage risk is lifelong and often has an environ-
mental trigger, such as minor trauma.28,29 Although there is 
no specific treatment, diagnosis is useful because patients can 
be counseled to avoid contact sports and anticoagulation, and 
mothers of affected fetuses could undergo planned cesarean 
section to reduce hemorrhage risk related to birth trauma.
Deficiency of Adenosine Deaminase 2
Deficiency of adenosine deaminase 2 (ADA2) is a rare 
pediatric genetic arteriopathy caused by loss-of-function 
recessively inherited mutations in CECR1 (cat eye syn-
drome chromosome region, candidate 1), resulting in an 
autoinflammatory vasculitis. Deficiency of adenosine de-
aminase 2 leads to abnormal endothelial and leukocyte de-
velopment and differentiation.30 A polyarteritis nodosa-like 
presentation is common. Systemic inflammatory features 
include livedoid rash, intermittent fevers, hypertension, 
raised inflammatory markers, and hypogammaglobulinae-
mia. Neurological features include lacunar and hemor-
rhagic stroke, peripheral, and cranial neuropathies.30,31 As 
many mutations in CECR1 have been described, with wide 
MM or stenosis ELN
MM-like with absent basal 
collaterals and abnormally 
straight intracranial arteries
ACTA2
MM-like, straight intracranial 
arteries, and profuse basal 
collaterals
MYH11
MM BRCC3/MTCP1
MM with posterior circulation 
involvement
GUCY1A3
Tortuous cerebral arteries ATP7A
Intra and extracranial 
dissections and aneurysms
SLC1A10
ABCC6 indicates pseudoxanthoma elasticum; AD, autosomal dominant; AR, 
autosomal recessive; ATP7A, Menke disease; CBS, Homocysteinuria; CECR1, 
adenosine deaminase 2 (ADA2) deficiency; ELN, Williams syndrome; GLA, 
Fabry disease; HBB, sickle cell disease; HTRA1, Cerebral autosomal recessive 
arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL); 
JAG1, Alagille syndrome; MM, moyamoya; NF1, Neurofibromatosis type 1; 
NOTCH3, Cerebral autosomal dominant arteriopathy with subcortical infarcts 
and leukoencephalopathy (CADASIL); PCAIS, posterior circulation arterial 
ischemic stroke; PCNT, Microcephalic osteodysplastic primordial dwarfism 
type II; PDA, patent ductus arteriosus; SAMHD1, Aicardi-Goutieres syndrome; 
SLC2A10, arterial tortuosity syndrome; TAAD, thoracic aorta aneurysm and 
dissection; and XLR, X linked recessive.
Table. Continued
  
Genetic Mutation 
(Disease Name Given 
Below if Different)
Peripheral pulmonary 
stenosis
JAG1
Dilated cardiomyopathy BRCC3/MTCP1
LVH, high output heart failure HBB
Systemic hypertension BRCC3/MTCP1, 
GUCY1A3, and CECR1
Peripheral artery disease ABCC6
Renal Cysts COL4A1 and COL4A2
Hematuria and renal failure COL4A1, COL4A2, and 
HBB
Proteinuria and renal tubular 
dysfunction
GLA
Bladder dysfunction ACTA2
Hepatic Cholestasis and bile duct 
paucity
JAG1
Skeletal X rays Sphenoid dysplasia NF1
Butterfly vertebrae JAG1
Spondylosis deformans HTRA1
Skeletal dysplasia PCNT
Blood 
investigations
Low platelets GUCY1A3
Raised HbF on hemoglobin 
electrophoresis
HBB
Raised inflammatory 
markers and 
hypogammaglobulinaemia
CECR1
Raised creatine kinase COL4A1 and COL4A2
Brain imaging
Porencephaly COL4A1 and COL4A2
Infarction and hemorrhage COL4A1, COL4A2, 
ATP7A, GLA (PCAIS 
more common), CECR1 
(lacunar infarcts), 
ABCC6 (lacunar 
infarcts), and HBB
White matter signal 
abnormalities preceding 
symptom onset
NOTCH3 and HTRA1
Unidentified bright objects 
and hamartomas
NF1
Basal ganglia calcification 
and leukoencephalopathy
SAMHD1
Craniosynostosis and Chiari 
malformation
SLC2A10
Arterial imaging
MM and aneurysm or 
stenosis
COL4A1, COL4A2, 
NF1, GUCY1A3, JAG1, 
SAMHD1, PCNT, and 
HBB
Table. Continued
  
Genetic Mutation 
(Disease Name Given 
Below if Different)
(Continued )
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phenotypic variation, pathogenesis should be confirmed by 
ADA2 functional enzyme assay.31 Anti–TNF-α therapy is 
useful because ADA2 functions as an important regulator of 
immune development.31
Environmental Associations With Childhood 
AIS and Cerebral Arteriopathy
Although genetic disorders may confer susceptibility to 
arteriopathy, environmental factors like infection and 
trauma may be important second hits to express the phe-
notype or to precipitate AIS in a child with a preexisting 
arteriopathy. The VIPS study has provided major insights 
into the role of infection and inflammation in AIS and 
arteriopathy. This was a rigorous, National Institutes of 
Health–funded international study of 355 prospectively 
enrolled children with AIS and 354 age-matched controls, 
including review of clinical and radiographic information, 
serum sampling, and follow-up for at least 1 year;32 find-
ings will be discussed below.
Inflammation in Childhood Cerebral 
Arteriopathy and AIS
Inflammation is triggered by tissue injury from any cause, 
such as infection, when inflammatory cells helpfully de-
stroy infected host cells in a transient and localized response. 
Inflammation becomes pathological when it is dispropor-
tionate to the tissue injury, occurring at a distant site, or of 
prolonged duration.33 Inflammation contributes to AIS path-
ogenesis through several mechanisms. Circulating immune 
mediators can trigger activation of the coagulation system 
and platelet aggregation, promoting thrombus formation. This 
could compound other AIS risk factors: for example, inflam-
mation could promote intracardiac clot formation in a child 
with congenital heart disease. Inflammation can also mediate 
arterial endothelial injury, disrupting vascular homeostasis, 
potentially leading to arteriopathy. Infection has been associ-
ated with impaired vascular endothelial function in children.34 
In turn, impaired endothelial function may be associated with 
recurrent AIS in cerebral arteriopathy—circulating indices of 
endothelial function in a cohort of children with AIS and ce-
rebral arteriopathy were different between those with a mono-
phasic course compared with recurrent AIS. Children with 
recurrent AIS had significantly higher markers of endothelial 
injury, thought to reflect ongoing vessel wall damage,35 as 
well as biomarkers of impaired endothelial repair response.36 
Ischemia itself is a trigger for inflammatory cascades in the 
brain, resulting in cell death and further inflammation, exacer-
bating the ischemic injury.37
Laboratory and Imaging Biomarkers 
of Inflammation in Pediatric Cerebral 
Arteriopathy
The VIPS study hypothesized that children with arteriopathic 
AIS would have a distinct pattern of inflammatory biomark-
ers compared with children with cardioembolic or idiopathic 
AIS and that these would predict arteriopathy progression and 
recurrent AIS. Elevated inflammatory biomarkers in AIS sug-
gest the presence of ongoing inflammation,38,39 although could 
be a result of downstream effects of ischemia. To minimize the 
effects of AIS itself, the VIPS study analyses were adjusted 
for infarct size, seizures, and timing of sample collection. The 
study found that serum levels of 3 of the 4 inflammatory bio-
markers measured differed by AIS pathogenesis. The cardio-
embolic group had higher concentrations of high-sensitivity 
C-reactive protein and myeloperoxidase than other groups; 
the cardioembolic and arteriopathic groups had higher serum 
amyloid A than the idiopathic group. In the arteriopathic 
group, higher high-sensitivity C-reactive protein and serum 
amyloid A predicted recurrent AIS.40 Although speculative, 
these differences in biomarkers could reflect the varied role of 
inflammation in AIS, for example, prothrombotic in children 
with structural heart disease or promoting endothelial injury 
in arteriopathy, as discussed above.
Classification of arteriopathy currently relies on luminal 
imaging techniques—magnetic resonance angiography, 
computed tomographic angiography, and digital subtraction 
angiography, which give little information on the disease 
process in the arterial wall. Vessel wall imaging is an emerg-
ing technique that directly images the arterial wall using 
high-resolution magnetic resonance imaging. Vessel wall 
enhancement may represent inflammation,41 and, although 
requiring validation, vessel wall imaging may help predict 
progressive arteriopathy in childhood AIS.42 Further work is 
needed to fully understand the investigative role of vessel 
wall imaging in childhood.
Infection, Vaccination, and Childhood AIS
Although unsurprisingly central nervous system and systemic 
infection are associated with AIS, there is now clear evidence 
that trivial viral infection transiently increases risk of child-
hood AIS. Up to one-third of cases of pediatric AIS report in-
fection in preceding weeks.1,43,44 In the VIPS cohort, infection 
in the week preceding stroke (or interview for controls) con-
ferred a 6-fold increased risk of AIS. Infections were mostly 
upper respiratory tract, and were common across all stroke 
subtypes, with a low use of vasoactive cold remedies.45 A 
6-fold increase in AIS risk still results in a low absolute risk, 
so additional factors are likely to be involved.
Interestingly, the VIPS study found that undervaccination 
was an independent risk factor for AIS in an age-adjusted 
multivariate logistic regression model; odds ratio, 8.2.45 This 
is despite most infections being identified as upper respi-
ratory tract, which are not vaccinated against. Vaccination 
could have a broader immune benefit which affects the in-
flammatory response, or it may indirectly prevent additional 
infections.46
Further research in the VIPS II study will attempt to better 
understand the paradox of a common risk factor like child-
hood infection and a rare outcome like childhood AIS. It will 
use next-generation sequencing for broad, unbiased detection 
of pathogens, testing the hypothesis that unusual combina-
tions of infections, or unusual strains of infection, explain this 
exposure paradox. It will also use multiplex bead array testing 
to measure serum levels of 16 immune mediators, testing the 
hypothesis that the paradox is explained by an abnormal in-
flammatory response to infection.47
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Specific Bacterial Infections
Severe bacterial infections can be complicated by AIS because 
of activation of the coagulation cascade, septic emboli, vas-
cular tissue injury, and inflammation. Bacterial meningitis can 
result in a secondary vasculitis as the basal cerebral arteries 
are exposed to purulent exudate and direct spread of inflam-
mation. Although vaccinations have dramatically reduced 
the incidence of bacterial meningitis in developed countries, 
Salmonella species and Streptococcus pneumoniae were the 
most common cause of pediatric meningitis complicated by 
AIS in 1 large prospective study.48 Stroke is a common com-
plication of tuberculous meningitis, occurring in one-third 
of cases because of a particularly aggressive inflammatory/
infectious basal vasculopathy.49 Other bacterial agents report-
edly associated with stroke include Mycoplasma pneumonia, 
Borrelia burgdorferi, Haemophilus influenza, and Chlamydia 
pneumoniae.33
Specific Viral Infections
Post-varicella zoster (VZV) arteriopathy typically affects 
previously healthy young children, 3 to 4 months after 
chickenpox infection (within 12 months to fit diagnostic 
criteria). VZV infects the trigeminal nerve and from there 
gains access to cerebral vessels, directly invading vessel 
walls causing an inflammatory response, with enhancement 
on vessel wall imaging, CSF pleocytosis, and lymphocytic 
infiltration on biopsy.37 The radiological pattern is of focal 
stenosis of the proximal middle cerebral artery and basal 
ganglia infarction.50 This is in contrast to VZV vasculitis, 
largely described in adults, which occurs after VZV reactiv-
ation (herpes zoster). VZV vasculitis presents with more dif-
fuse neurological features, has a less consistent angiographic 
pattern, often with patchy multifocal involvement.33 Less 
commonly aneurysms and dissection occur. VZV DNA or, 
more helpfully, anti-VZV antibodies in CSF aid diagnosis. 
Anti-inflammatory and antiviral treatment (corticosteroids 
and acyclovir) are recommended. In children with the typical 
clinical and radiographic findings of post-varicella arteriop-
athy, CSF studies are not always performed, and evidence 
for benefit of treatment of positive findings of VZV DNA or 
antibodies is lacking. The overlap between these entities re-
mains open (Figure 2).
The VIPS study performed herpesvirus serologies in 326 
acute AIS cases, including 187 paired acute and convalescent 
samples. Serological evidence of acute herpesvirus infection 
doubled the risk of AIS, across all subtypes (even after adjust-
ing for age, race, and socioeconomic status). Almost half of 
the children with paired samples had serological evidence 
of acute herpesvirus infection. Herpes simplex virus type 1 
was most common, and most infections were asymptomatic.51 
This association could be partly explained by similar mecha-
nisms to VZV arteriopathy. In addition, a common mechanism 
Figure 2. Arteriopathy following varicella zoster (VZV) infection. Axial T2-weighted brain MRI (A) and time of flight MRA (B) of the circle of Willis from an 
8-y-old girl who presented with transient right-sided weakness. She had uncomplicated chickenpox 3 mo earlier. A shows multifocal areas of infarction in 
the territory of the left middle cerebral artery (MCA); B shows a focal area of flow abnormality in the proximal left MCA. She was otherwise well with no sys-
temic markers of inflammation. A, Diagnosis of focal cerebral arteriopathy was made, and she was treated with aspirin (5 mg/kg per d). Two weeks later, she 
presented with a more profound episode of right hemiparesis and dysphasia. There was no change on brain MRI; however, the MRA (C) showed a more ex-
tensive abnormality in the left MCA, confirmed on catheter angiography that also revealed occlusion of the right A1 segment (D). CSF examination showed 
no cells but a positive VZV PCR and VZV IgG. She was treated with intravenous acyclovir for 2 wk and then oral acyclovir for 3 mo in total. She had no further 
clinical events; reimaging was stable and repeat CSF examination unremarkable.
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across AIS subtypes is theorized: inflammatory endothelial in-
jury promoting cardiac thrombus or cerebral arteriopathy.
Stroke occurring in children with HIV 1 infection is likely 
to be multifactorial in origin. Direct HIV1 infection of the ar-
terial wall may cause arteriopathy. AIS may also result from 
opportunistic infection, drug effects (toxicity, dyslipidemia, 
and atherosclerosis), prothrombotic factors, and inflammatory 
components.52
Other viral infections, such as parvovirus, enterovirus, and 
influenza A, have been reported in the setting of childhood 
AIS. It is likely that some associated viruses contribute to 
stroke risk via common mechanisms, activating both proin-
flammatory and prothrombotic pathways.
Trauma
Significant head trauma (requiring medical attention) in the 
previous week conferred an almost 40-fold increased odds of 
AIS compared with matched controls without trauma expo-
sure in a large population-based study. More severe trauma 
was more strongly linked to AIS.44 Mechanisms of AIS after 
major head trauma may be carotid or vertebral artery trauma 
or dissection, or vasospasm.53
Arterial dissection and AIS after minor head trauma may 
be because of a more complex interplay of factors, such as 
local inflammation of blood vessels primed by infection or ge-
netic predisposition. Although several rare hereditary connec-
tive tissue disorders (eg, Marfan syndrome and Ehlers-Danlos 
type IV) confer a particularly high risk of dissection, electron 
microscopy of skin biopsies in patients with arterial dissec-
tion reveals a high proportion with structural abnormalities 
of collagen fibrils and elastic fibers.54,55 Patients with cervical 
arterial dissection are also more likely to have clinically de-
tectable connective tissue abnormalities, such as joint laxity 
or hyperextension.56 Case-control studies in adults provide ev-
idence of an association between minor acute infection and 
arterial dissection.57,58 Taken together, these studies support 
the hypothesis that environmental exposures like trauma and 
infection can act as triggers for arteriopathy (in this case, dis-
section) in the genetically predisposed.
A distinctive clinical phenotype of basal ganglia infarction 
after minor injury has been reported in infants, postulated to 
result from vasospasm in lenticulostriate perforator arteries.59 
Lenticulostriate artery mineralization has been described in 1 
cohort,60 possibly reflecting an underlying vulnerability, but 
has not been replicated elsewhere.
Treatment
Recurrence rates in childhood AIS with arteriopathy are 
high, despite antithrombotic therapy. In VIPS, 21% of chil-
dren with definite arteriopathy had a recurrence (the highest 
in moyamoya), compared with 4.5% with idiopathic AIS and 
8.1% for cardioembolism.7 Improved management of arte-
riopathy, including prevention of recurrence, is a priority in 
childhood AIS.
As we have illustrated, inflammation appears to be a key 
mechanism of AIS and recurrence and, therefore, may underlie 
arteriopathy progression or recurrence. Anti-inflammatory 
therapies are an obvious therapeutic target, but there are 
safety concerns in the context of recent infection. Although 
anecdotally corticosteroids have been used in post-varicella 
arteriopathy, and focal cerebral arteriopathy of childhood, a 
recent systematic review of 34 studies concluded that robust 
evidence of efficacy is lacking.61 A recent physician survey 
concluded that a clinical trial of corticosteroids in focal cere-
bral arteriopathy of childhood is a priority (with concomitant 
use of acyclovir in post-varicella arteriopathy).62 However, a 
recent analysis of 84 UK AIS cases did not find a high recur-
rence rate in focal cerebral arteriopathy of childhood.63 The 
variable recurrence rate in different cohorts, and in different 
AIS subtypes, challenges the concept of grouping all AIS 
cases together for an interventional trial. Rigorous identifica-
tion of homogenous disease entities and mechanism-specific 
trials in subgroups would be a more logical approach.
Therapies that inhibit smooth muscle cell proliferation is 
another potential avenue to explore in pediatric cerebral arteri-
opathy, particularly in those with genetic smooth muscle dys-
function syndromes, for example, imatinib or statins may have 
a modifying effect.8,64
Improving rates of routine childhood vaccination should 
be encouraged as a primary stroke prevention method. 
Varicella-zoster vaccination is recommended by the World 
Health Organization in counties who assess a significant 
public health burden from VZV65; however, it is not part of the 
UK routine vaccine schedule.
VIPS II will test for a large number of immune media-
tors to delineate the pathway of inflammation in different AIS 
subtypes.47 Understanding the inflammatory response better 
could lead to more targeted immunotherapy in future. This 
study also aims to advance understanding of the role of spe-
cific pathogens in arteriopathy, which could also guide treat-
ment with antibiotics or antiviral therapy.
Conclusions
We have outlined some single-gene disorders that are associ-
ated with pediatric AIS to illustrate multifactorial pathogenesis 
of arteriopathy and the interplay between genetic and environ-
mental factors. The latter are common, for example, minor in-
fection or trauma. Inflammation is an important mechanistic 
final common pathway. A trial of corticosteroids in focal ce-
rebral arteriopathy of childhood is planned, but a one-size-
fits-all approach to pediatric AIS trials should be applied with 
caution because different phenotypes have varying disease 
trajectories, further varying between cohorts. Further defining 
specific arteriopathy subtypes, and disease-specific targets for 
trials, should be an immediate priority.
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